As Colorado surpasses a 47 percent rate of its population being fully immunized (with 12 counties surpassing 70 percent), researchers continue to expand the study of the vaccines on children as young as five years old. The CCTSI's Pediatric Clinical and Translational Research Center (CTRC) is playing a major role as it conducts the Pfizer BioNTech COVID-19 vaccine trial for children ages 5 - 11.
When the pandemic hit last year, the CCTSI responded by creating the COVID-19-Rapid Research Pilot Program. Fifty-five people applied and the CCTSI chose four awardees. More than one year later, read about what they learned.
A new $8.7 million grant from the National Institutes of Health (NIH) will enable researchers to test the real-world effectiveness of a promising treatment for high-risk COVID-19 outpatients and to study the best way to reach the population who is at the greatest risk of serious disease and hospitalization.
Nokoff (pictured below) is currently leading a longitudinal observational study of transgender youth—half who have received a puberty blocker and half who have not, before and after they start testosterone clinically—to better understand the effect of puberty blockers and testosterone on health.
The CCTSI's leadership training program for doctors and researchers (LITeS) celebrates its tenth year of teaching physicians and scientists to work together for the welfare of patients and for the academic institutions where they work.
Why know that exercise is good for us. Professor Wendy Kohrt aims to find out why. She is leading an exercise study called MoTrPAC to develop a so-called molecular map of tissue-specific and circulating signals produced by physical activity.